[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"ramucirumab\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:ramucirumab":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,40],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":4},"100604090","maic-of-fruquintinib-plus-paclitaxel-versus-ramucirumab-plus-paclitaxel-in-advanced-ggej-adenocarcinoma-100604090",false,"NCT07144995","MAIC of Fruquintinib Plus Paclitaxel Versus Ramucirumab Plus Paclitaxel in Advanced G\u002FGEJ Adenocarcinoma","Adjusted Indirect Treatment Comparison of Fruquintinib-based Therapy Versus Standard Care in Advanced Gastric\u002FGastroesophageal Junction Adenocarcinoma: A MAIC Analysis.","Inclusion Criteria:\n\n* Histologically confirmed gastric\u002FGEJ adenocarcinoma\n* Advanced or metastatic disease\n* ECOG 0-1\n* Received either fruquintinib + paclitaxel or reference regimen\n* Available baseline characteristics for matching variables\n\nExclusion Criteria:\n\n* Missing key outcome data\n* Incomplete baseline characteristics for \\>2 matching variables\n* Prior fruquintinib exposure (control arm only)","ALL","18 Years",{"count":19,"type":20},1143,"ESTIMATED","OBSERVATIONAL","This anchored matching-adjusted indirect comparison (MAIC) evaluates the relative efficacy of fruquintinib-paclitaxel (using IPD from the FRUTIGA trial, n=703) versus ramucirumab-paclitaxel (using published AgD from RAINBOW-Asia, n=440) in advanced gastric\u002FGEJ adenocarcinoma. Baseline characteristics are adjusted via entropy balancing weights. Primary endpoint is progression-free survival (PFS) analyzed by Bucher method; secondary endpoints include overall survival (OS) and objective response rate (ORR). Sensitivity analyses comprise restricted mean survival time (RMST) analysis and simulated treatment comparison (STC).",[24,25,26,27],"Advanced Gastric Cancer","Gastroesophageal Junction Adenocarcinoma","Fruquintinib","Ramucirumab","NOT_YET_RECRUITING","2025-08-20",{"date":31,"type":32},"2025-08-28","ACTUAL",{"date":34,"type":20},"2025-09-05",{"date":36,"type":20},"2026-12-31",{"name":38,"class":39},"Sun Yat-sen University","OTHER",{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":4,"eligibilityCriteria":46,"healthyVolunteers":11,"sex":16,"minAge":47,"maxAge":4,"enrollmentInfo":48,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":50,"conditions":51,"keywords":4,"overallStatus":55,"whyStopped":4,"lastUpdateSubmitDate":56,"lastUpdatePostDateStruct":57,"startDateStruct":59,"completionDateStruct":61,"leadSponsor":63,"locationsCount":65},"100553751","predicting-peripheral-neuropathy-of-paclitaxel-for-gastric-cancer-100553751","NCT06490159","Predicting Peripheral Neuropathy of Paclitaxel for Gastric Cancer","Predicting Peripheral Neuropathy of Paclitaxel in Second-line Chemotherapy for Gastric Cancer","Inclusion Criteria:\n\n1. unresectable or recurrent Gastric cancer (GC) histologically confirmed to be primary adenocarcinoma of the stomach.\n2. age over 20 years.\n3. Eastern Cooperative Oncology Group performance status score of 0-2.\n4. written informed consent following full study information is provided to the patient.\n5. progression or intolerance for first-line chemotherapy comprising fluorinated pyrimidine and platinum anticancer drugs (cisplatin or oxaliplatin) for advanced GC.\n6. presence of evaluable lesions as confirmed using a computed tomography (CT) or magnetic resonance imaging.\n\nExclusion Criteria:\n\n1. Patients with a life expectancy of shorter than 3 months\n2. Patients with severe complications (angina pectoris, myocardial infarction, or arrhythmia) or uncontrollable diabetes mellitus, blood hypertension, or bleeding tendency.\n3. Patients with a history of serious allergic reactions or serious drug allergy.\n4. Patients with a clinically relevant mental disorder that prohibits response to questionnaires.\n5. Patients for whom the attending physician considered that enrollment in the study is inappropriate.","20 Years",{"count":49,"type":20},150,"Although advances in chemotherapy have improved the prognosis of gastric cancer patients, many patients still suffer from adverse events. Therefore, it is necessary to establish personalized treatment by identifying patients at high risk for side effects. Although paclitaxel-based therapy is the standard second-line treatment, peripheral neuropathy is a troublesome adverse event. The purpose of this study is to establish a liquid biopsy assay to predict paclitaxel-induced peripheral neuropathy in gastric cancer patients.",[52,53,54,27],"Gastric Cancer","Chemotherapy-induced Peripheral Neuropathy","Paclitaxel","RECRUITING","2025-07-09",{"date":58,"type":32},"2025-07-11",{"date":60,"type":32},"2018-10-01",{"date":62,"type":20},"2026-06-18",{"name":64,"class":39},"City of Hope Medical Center",1]